Extensive Stage Small Cell Lung Cancer clinical trials

Explore recruiting extensive stage small cell lung cancer clinical trials.

Recruiting extensive stage small cell lung cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Extensive Stage Small Cell Lung Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A single-arm phase II-study to confirm efficacy and feasibility of tarlatamab treatment in patients with extensive stage small-cell lung cancer with poor performance status (SPACE-T) [without IMPD-Q]

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide with or Without Tiragolumab (Anti-Tigit Antibody) in Patients with Untreated Extensive-Stage Small Cell Lung Cancer

Greece, Italy, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

IFCT-2203 TAXIO A phase II study assessing the efficacy of etoposide free chemotherapy plus durvalumab (MEDI4736) in first line extensive disease Small Cell Lung Cancer (SCLC)

France, Luxembourg

Therapeutic exploratory (Phase II) EU CTIS Study details

DAREONTM-9: A study to test how well different doses of BI 764532 are tolerated by people with small cell lung cancer when taken together with a single agent chemotherapy

Germany, France, Poland

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Global, Multicenter, Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Belgium, Poland, Hungary, Germany, Italy, Romania +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

Germany, Poland, Belgium, Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

Extensive Stage Small Cell Lung Cancer trials by city

Extensive Stage Small Cell Lung Cancer in Toronto Extensive Stage Small Cell Lung Cancer in Vancouver Extensive Stage Small Cell Lung Cancer in Montreal Extensive Stage Small Cell Lung Cancer in Calgary Extensive Stage Small Cell Lung Cancer in Edmonton Extensive Stage Small Cell Lung Cancer in Ottawa Extensive Stage Small Cell Lung Cancer in Winnipeg Extensive Stage Small Cell Lung Cancer in Quebec City Extensive Stage Small Cell Lung Cancer in Hamilton Extensive Stage Small Cell Lung Cancer in Kitchener Extensive Stage Small Cell Lung Cancer in London Extensive Stage Small Cell Lung Cancer in Halifax Extensive Stage Small Cell Lung Cancer in New York Extensive Stage Small Cell Lung Cancer in Los Angeles Extensive Stage Small Cell Lung Cancer in Chicago Extensive Stage Small Cell Lung Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease